09/29/2026 | Press release | Archived content
Tennessee Attorney General Jonathan Skrmetti urges consumers who purchased certain generic prescription drugs to check their eligibility for compensation. The funds come from settlements with generic drug manufacturers accused of unlawfully conspiring to raise drug prices.
This month, the U.S. District Court for the District of Connecticut granted preliminary approval of a plan filed by Tennessee and a coalition of 47 other states and territories to distribute settlement funds paid by generic drug manufacturers. The settlements resolve allegations that the companies conspired with competitors to inflate prices of generic prescription drugs.
"Corporate collusion to raise drug prices is illegal, and we won't put up with it in Tennessee," said Attorney General Jonathan Skrmetti. "When companies break the law, we're glad work with AGs from around the country in a bipartisan fight to hold those companies accountable for their antitrust violations. Tennessee consumers who were fleeced by inflated generic drug prices should check to see if they qualify for restitution payment."
The multistate coalition previously announced settlements with Glenmark, Lannett, Bausch, Apotex, Heritage and Heritage's parent company, Emcure, totaling approximately $96.5 million. The coalition's distribution plan aims to return millions of dollars from those settlement funds to consumers and others who may have been harmed by alleged overcharges for generic drugs covered by the settlements.
Consumers who purchased certain generic prescription drugs between May 2009 and December 2019 may be eligible for compensation. Eligibility depends on the specific drug purchased and other requirements.
Consumers can determine whether they may qualify by:
Consumers may also register through the settlement website to receive notice about the claims process. Claim forms will be made available through the settlement website and other means when the claims process opens.